Skip to content
Open access

HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy

Sep 2026 · Journal of Antimicrobial Chemotherapy · Vol 81 · 0 citations · 18 references
Medicine

TL;DR

These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway and support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand.

Abstract

Abstract Background Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid variation alongside emerging integrase resistance is increasingly important. Whether DTG resistance pathways coexist with known capsid resistance mutations in West African epidemics remains poorly described. Methods We performed deep sequencing of 87 HIV-1 samples from adults (n = 47) and paediatric participants (n = 40) failing DTG-based antiretroviral therapy in Nigeria. Resistance mutations were interpreted using Stanford HIVdb and IAS-USA criteria, with resistance estimates based on gene- or drug-panel-specific denominators. Low-frequency variants were assessed at 2%, 5%, 10% and 20% read-frequency thresholds. Capsid mutations associated with LEN resistance were characterized, structurally mapped and compared to global sequence data. HIV-1 subtype and recombinant forms were assigned using COMET HIV-1 v2.4. Results At consensus, predicted resistance to ≥1 integrase strand transfer inhibitor (INSTI) was detected in 13/50 integrase-genotypable participants (26.0%; 95% CI 15.9%–39.6%), including 5/50 with a major INSTI resistance mutation. Reduced predicted susceptibility specifically to DTG was present in 6/50 (12.0%; 95% CI 5.6%–23.8%). G118R was detected in 4/50 participants at consensus, while Q148H/K/R and N155H were absent. In exploratory deep-sequencing analysis, G118R was detected in 8/47 participants with sufficient codon-level coverage at the ≥20% read-frequency threshold. No known primary LEN resistance mutation was detected among 33 participants with complete coverage of all six primary resistance positions (0/33; 95% CI 0%–10.4%); T107A, a polymorphic capsid substitution of uncertain effect on LEN susceptibility, was detected in in 3/33 individuals where sequence could be evaluated. Conclusions These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand.

Read PDF

Similar papers

Open access Sep 2026

Baseline Lenacapavir Resistance and Capsid Variability in Bulgaria: A Next-Generation Sequencing Study of Newly Diagnosed HIV-1 Infections

Lenacapavir, the first approved HIV-1 capsid inhibitor, is now being introduced for both treatment and pre-exposure prophylaxis, yet the capsid-coding region lies outside the pol fragment examined in routine genotypic resistance testing, and baseline data on capsid variability remain scarce, particularly in epidemics d...

I. Alexiev, Aleksandra Partsuneva, R. Dimitrova et al. · 0 citations
Open access Sep 2026

HIV-1 drug resistance during the transition from NNRTI- to INSTI-based therapy in Thailand: prevalence, resistance-associated mutations, and antiretroviral

Although INSTI-associated resistance emerged following the implementation of INSTI-based therapy in Thailand, its prevalence remained low, supporting the continued effectiveness of dolutegravir-based regimens and Continuous HIVDR surveillance remains essential to optimize long-term treatment outcomes.

Srivilai Trakulkaseamsiri, S. Surinkaew, Supanida Utthapa et al. · 0 citations
Review Open access Sep 2026

HIV-1 Drug Resistance Mutations in Children: A Systematic Review of Global Genotypic Evidence (2014–2026)

HIV-1 infection in children remains a major public health challenge, particularly in resource-limited settings where access to antiretroviral therapy (ART) and routine virological monitoring is limited. The emergence of HIV-1 drug resistance mutations (DRMs) compromises treatment efficacy and threatens long-term therap...

Ghita Jouf, Alae Bekkouri Alami, Najwa Maazaz et al. · 0 citations
Open access Jan 2026

Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz‐Based Regimens in Patients With V179D/E Mutations in Guangzhou, China

Aim To analyze the prevalence of human immunodeficiency virus type 1 (HIV‐1) drug resistance mutations (DRMs) and compare the therapeutic outcomes of different antiretroviral treatment regimens in newly diagnosed HIV‐1‐infected patients with the V179D/E mutation. Methods This study included newly diagnosed HIV‐1‐infect...

Xingrong Zheng, Yun-Fei Xiao, Ye-Qiong Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.